

## Prescribing Information

### Tivicay<sup>▼</sup> dolutegravir 10mg, 25mg and 50mg tablets

See Summary of Product Characteristics before prescribing

**Indication:** HIV in >6 years and  $\geq 15$ kg as part of combination therapy. **Dosing:** *Adults & adolescents  $\geq 40$ kg:* 50mg once daily with or without food if no proven/ suspected integrase resistance. Children 6 to <12 years: dose according to bodyweight: 15-<20kg: 20mg once daily (2x10mg); 20-<30kg: 25mg once daily; 30-<40kg: 35mg once daily (1 x 25mg + 1 x 10mg); When co-administered with efavirenz, nevirapine, tipranavir/ritonavir, etravirine (without boosted PI), carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John's Wort or rifampicin, Tivicay 50mg twice daily in adults/adolescents or the weight-based once daily dose twice daily in paediatric patients. *Adults with proven or suspected integrase resistance:* 50mg twice daily preferably with food. Limited data in paediatric patients with proven/suspected integrase resistance. *Elderly:* Limited data in 65+ yrs. Caution in severe hepatic impairment.

**Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide.

**Warnings/precautions:** Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immediately if suspected. The two-drug regimen of dolutegravir and lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine. Risks of osteonecrosis, immune

reactivation syndrome. Monitor LFTs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with etravirine requires boosted PI or increased dose of dolutegravir. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. **Pregnancy/ lactation:** Before initiating dolutegravir, women of childbearing potential (WOCBP) should undergo pregnancy testing. WOCBP who are taking dolutegravir should use effective contraception.

Dolutegravir should not be used during the first trimester due to the potential risk of neural tube defects, unless there is no alternative.

Dolutegravir should only be used during the second and third trimester of pregnancy when the expected benefit justifies the potential risk to the foetus. Avoid breast-feeding. **Side effects:** See SmPC for full details. Headache, GI disturbance, insomnia, abnormal dreams, depression, anxiety, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, arthralgia, myalgia, hypersensitivity, suicidal ideation or suicide attempt, acute hepatic failure.

**Basic NHS costs:** £498.75 for 30 x 50mg tablets (EU/1/13/892/001). £99.75 for 30 x 10mg tablets (EU/1/13/892/003). £249.38 for 30 x 25mg tablets (EU/1/13/892/005). MA holder: ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Netherlands. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

**POM** S1A

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.

Date of approval: December 2018

Zinc code: UK/DLG/0055/13(16)

Adverse events should be reported. For the UK, reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for **MHRA Yellowcard** in the **Google Play** or **Apple App store**. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, [medsafety@hpra.ie](mailto:medsafety@hpra.ie). Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

## Epivir - Lamivudine 300mg tablets

### Prescribing Information

See Summary of Product Characteristics (SmPC) before prescribing

**Indications:** HIV in adults, adolescents and children weighing at least 25 kg as part of combination

therapy. **Dose:** Adults: one 300mg tablet daily with or without food. See SmPC for dosage in children and adolescents. Additional formulations available: 150mg tablets and Oral Solution (10mg/mL) – see SmPCs. *Elderly:* No specific data. *Renal*

*impairment:* Creatinine clearance <50ml/min: see SmPC for dosage adjustment. *Hepatic impairment:* no dose adjustment required. **Contraindications:**

Hypersensitivity to any ingredient.

**Warnings/precautions:** High risk of virological failure (when used in a triple nucleoside regimen), immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Use with cladribine,

emtricitabine or high doses of co-trimoxazole not recommended. When possible, avoid chronic co-administration of sorbitol or other osmotic acting alcohols (see SmPC section 4.5). If unavoidable, consider more frequent viral load monitoring.

**Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SmPC for full details. Headache, GI disturbance, insomnia, cough, nasal symptoms, rash, alopecia, arthralgia, muscle disorders, fatigue, malaise, fever, blood dyscrasias, pancreatitis, hepatitis, angioedema, rhabdomyolysis, lactic acidosis, peripheral neuropathy. Transient increases in liver enzymes.

**Basic NHS costs:** 30 tablets: £157.51

EU/1/04/298/002. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

POM S1A

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Date of approval: June 2018

UK/3TC/0001/18

Adverse events should be reported. For the UK, reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for **MHRA Yellowcard** in the **Google Play or Apple App store**. Adverse events should also be reported to GSK on 0800 221441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPR; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, [medsafety@hpra.ie](mailto:medsafety@hpra.ie). Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.